By Don Thompson for KFF Health News. Broadcast version by Suzanne Potter for California News Service reporting for the KFF ...

A November 2025 Kaiser Family Foundation poll found that 1 in 8 U.S. adults have tried a GLP-1 medication for weight loss, ...

According to the Centers for Disease Control and Prevention, 41.9 percent of U.S. adults were obese from 2017 to 2020.

The diabetes and weight?loss drug market has entered 2026 with extraordinary momentum, building on the explosive growth seen throughout 2025. According to global health information technology ...

California will end Medi-Cal coverage for popular weight-loss drugs like Wegovy starting Jan. 1, citing soaring pharmaceutical costs. Low-income residents losing coverage will be advised to rely on ...

Stopping GLP-1 weight loss drugs like Ozempic and Wegovy often leads to rapid weight regain and returning health risks.

Weight loss journeys are as unique as the individuals who embark on them. We all have different body types, lifestyles, health histories and goals that shape what we need to achieve lasting results.

Amycretin targets GLP-1 and amylin hormones, seen as potential best-in-class therapy Novo shares rise over 5% after amycretin trial results Amycretin aids significant weight loss and glucose control ...

For many Americans, the cost of trying to lose weight extends well beyond the scale. A new poll of 2,000 U.S. adults actively ...

Please provide your email address to receive an email when new articles are posted on . On average, people who stopped using weight loss drugs regained 0.4 kg monthly. The weight lost during treatment ...

Consumers are surrounded by food that is highly conducive to weight gain. No one likes dieting and very few have lasting success. But now weight-loss injections are seen as game changers, yielding ...

“Weight-loss methods, whether with pharmacotherapy or surgery, have to be mindful to avoid inducing these complications,” ...